<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900925-0148</DOCNO><DOCID>900925-0148.</DOCID><HL>   Technology:   Biogen Gets a Patent   In Europe for Version   Of Interferon Drug</HL><DATE>09/25/90</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   BGEN EUROP</CO><IN>MEDICAL AND BIOTECHNOLOGY (MTC)DRUG MANUFACTURERS (DRG)</IN><LP>   CAMBRIDGE, Mass. -- Biogen Inc. said it was awarded aEuropean patent for genetically engineered beta interferon,an experimental drug for treating various kinds of cancer andviral infections.   A naturally occurring form of the substance, which is madeby certain human cells, has been sold for several years invarious European countries, Biogen said. Last year, Biogenand Asta Pharma AG of West Germany, a division of Degussa AG,agreed to develop jointly a genetically engineered version ofthe drug for marketing in certain Western European countries.Biogen plans to develop the drug separately for marketing inthe U.S.</LP><TEXT>   Biogen's European patent covers DNA molecules, geneticallyaltered cells and methods employed in making a geneticallyengineered form of the drug, the company said. Clinical testsindicate the drug may be useful in treating a number ofdisorders, including hepatitis C, a liver disease; multiplesclerosis, a nerve disease; and cancers such as melanoma,brain tumors and lymphoma, Biogen said.</TEXT></DOC>